48 Alvarez-Sarmiento, Jessica y col.
29 US Food And Drug Administra-
tion (2016). Kovanaze. Available from:
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.
cfm?event=overview.process&ApplNo=208032 [Accessed
on 23 September 2019].
30 Capetillo J, Drum M, Reader A, Fowler S, Nusstein J, Beck
M. Anesthetic Efficacy of Intranasal 3 % Tetracaine plus
0.05 % Oxymetazoline (Kovanaze) in Maxillary Teeth. J
Endod. 2019; 45: 257–62.
31 Kumar A, Raj J. Knowledge, attitude, and practices regar-
ding the use of nasal spray anesthesia by dental practitio-
ners. Drug invent today. 2018; 10: 2023-28.
32 Hersh E, Saraghi M, Moore P. Intranasal tetracaine and
oxymetazoline: a newly approved drug formulation that
provides maxillary dental anesthesia without needles. Curr
Med Res Opin. 2016; 32: 1919–25.
33 Ciancio S, Hutcheson M, Ayoub F, Pantera E, Pantera C,
Garlapo D, et al. Safety and efficacy of a novel nasal spray
for maxillary dental anesthesia. J Dent Res. 2013; 92: 43S-
8S.
34 Hersh E, Saraghi M, Moore P. Two Recent Advances in
Local Anesthesia: Intranasal Tetracaine/Oxymetazoline and
Liposomal Bupivacaine. Curr Oral Health Rep. 2017; 4:
189–196.
35 Giannakopoulos H, Levin L, Chou J, Cacek A, Hutcheson
M, Secreto S, et al. The cardiovascular effects and phar-
macokinetics of intranasal tetracaine plus oxymetazoline:
preliminary findings. J Am Dent Assoc. 2012; 143: 872–80.
36 Higgins T, Hwang P, Kingdom T, Orlandi R, Stammberger
H, Han J. Systematic Review of Topical Vasoconstrictors
in Endoscopic Sinus Surgery. Laryngoscope. 2011; 121:
422–32.
37 Hersh E, Pinto A, Saraghi M, Saleh N, Pulaski L, Gordon
S, et al. Double-masked, randomized, placebo-controlled
study to evaluate the efficacy and tolerability of intrana-
sal K305 (3 % tetracaine plus 0.05 % oxymetazoline) in
anesthetizing maxillary teeth. J Am Dent Assoc. 2016; 147:
278–87.
38 Cacek A, Gobburu J, Gopalakrishnan M. Population Phar-
macokinetics of an Intranasally Administered Combination
of Oxymetazoline and Tetracaine in Healthy Volunteers. J
Clin Pharmacol. 2017; 57: 247–54.
39 Misra A, Shahiwala A. Novel drug delivery technologies in-
novative strategies for drug re-positioning, 1st ed. Springer
Singapore, 2019.
40 Laube B, Sharpless G, Vikani A, Harrand V, Zinreich S,
Sedberry K, et al. Intranasal Deposition of AccusprayTM
Aerosol in Anatomically Correct Models of 2-, 5-, and 12-
Year-Old Children. J Aerosol Med Pulm Drug Deliv. 2015;
28: 320–33.
41 Evans G, Yiming L. A phase 3, multi-center, randomized,
double-blind, parallel-groups clinical trial comparing the ef-
ficacy and safety of intranasally administered K-305 to pla-
cebo for anesthetizing maxillary teeth in pediatric patients.
2016 [citado 2 de abril de 2020]. Available from:URL:
https://www.fda.gov/downloads/Drugs/Development
ApprovalProcess/DevelopmentResources/UCM513665.pdf
42 Madurantakam P. Kovanaze Vs. Articaine in Achieving
Pulpal Anesthesia of Maxillary Teeth - Pediatric. 2019
[citado 2 de abril de 2020]. Available from: URL:
https://clinicaltrials.gov/ct2/show/NCT03962634
43 Szmuk P, Szmuk E, Ezri T. Use of needle-free injection sys-
tems to alleviate needle phobia and pain at injection. Expert
Rev Pharmacoenomics Outcomes Res. 2005; 5: 467–77.
44 Milani A, Froughreyhani M, Rahimi S, Zand V, Jafarabadi
Ma. Volume of Anesthetic Agents and IANB Success: A
Systematic Review. Anesth Prog. 2018; 65: 16–23.
45 Abazarpoor R, Parirokh M, Nakhaee N, Abbott P. A Compa-
rison of Different Volumes of Articaine for Inferior Alveolar
Nerve Block for Molar Teeth with Symptomatic Irreversible
Pulpitis. J Endod. 2015; 41: 1408–11.
46 Mikesell A, Drum M, Reader A, Beck M. Anesthetic Effi-
cacy of 1.8 mL and 3.6 mL of 2 % Lidocaine with 1:100,000
Epinephrine for Maxillary Infiltrations. J Endod. 2008; 34:
121–5.
47 Aggarwal V, Singla M, Miglani S, Kohli S, Sharma V,
Bhasin S. Does the volume of supplemental intraligamen-
tary injections affect the anaesthetic success rate after a
failed primary inferior alveolar nerve block? A randomized-
double blind clinical trial. Int Endod J. 2018; 51: 5–11.
48 Brunetto P, Ranali J, Ambrosano G, De Oliveira P, Groppo
F, Meechan J, et al. Anesthetic efficacy of 3 volumes of lido-
caine with epinephrine in maxillary infiltration anesthesia.
Anesth Prog. 2008; 55: 29–34.
49 Singla M, Subbiya A, Aggarwal V, Vivekanandhan P, Yadav
S, Yadav H, et al. Comparison of the anaesthetic efficacy
of different volumes of 4 % articaine (1.8 and 3.6 mL) as
supplemental buccal infiltration after failed inferior alveolar
nerve block. Int Endod J. 2015; 48: 103–8.
50 Pfeil L, Drum M, Reader A, Gilles J, Nusstein J. Anesthe-
tic Efficacy of 1.8 Milliliters and 3.6 Milliliters of 2 %
Lidocaine with 1:100,000 Epinephrine for Posterior Supe-
rior Alveolar VREELAND DL, READER A, BECK M,
MEYERS W, WEAVER J. An evaluation of volumes and
concentrations of lidocaine in human inferior alveolar nerve
block. J Endod. 1989; 15: 6–12.
51 Vreeland D, Reader A, Beck M, Meyers W, Weaver J. An
evaluation of volumes and concentrations of lidocaine in
human inferior alveolar nerve block. J Endod. 1989; 15:
6–12.
52 Nusstein J, Reader A, Beck F. Anesthetic efficacy of dif-
ferent volumes of lidocaine with epinephrine for inferior
alveolar nerve blocks. Gen Dent. 2002; 50: 372–5.
53 Parirokh M, Satvati S, Sharifi R, Rekabi A, Gorjestani H,
Nakhaee N, et al. Efficacy of combining a buccal infiltration
with an inferior alveolar nerve block for mandibular molars
with irreversible pulpitis. Oral Surg, Oral Med, Oral Pathol,
Oral Radiol, and Endod. 2010; 109: 468–73.
Revista OACTIVA UC Cuenca. Vol. 6, No. 1, Enero-Abril, 2021